The renoprotective effect of RAAS inhibitors may be partially mediated by limiting activation of the NF-κB pathway (Figure 2), known to be activated by angiotensin II in experimental CKD (Ruiz-Ortega et al., 2006). Here, NFKB1 is linked to chronic kidney disease.